Generics? No Thanks, We’re Glaxo

Others in Big Pharma may be stepping up their investment in generics, but GlaxoSmithKline’s new CEO isn’t going there. “I’ve got no interest in the classic U.S.-style generic marketplace,” he said during a recent interview in London. “It’s a different kind of business. It’s not just about low cost of production. It’s about your aggressiveness [...]